---
schema_version: "secwatch.filing_event.v1"
accession: "0000805928-24-000135"
form_type: "8-K"
ticker: "AXGN"
cik: "0000805928"
company_name: "Axogen, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T04:07:26.649189+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Axogen Q3 revenue $48.6M (+18% YoY), adjusted net income $3.1M; BLA accepted by FDA

## Summary
- Revenue $48.6M (+17.9% YoY); gross margin 74.9% vs 76.8% in prior year.
- Net loss $1.9M ($0.04/shr) vs $4.1M ($0.10/shr); adjusted net income $3.1M ($0.07/shr).
- Adjusted EBITDA $6.5M vs $2.4M in Q3 2023; cash $30.5M at quarter end.
- FDA accepted BLA for Avance Nerve Graft under standard review; PDUFA date Sept 5, 2025; no advisory committee planned.
- 2024 revenue guidance reaffirmed $182M-$186M; expects high end of gross margin range and cumulative net cash flow positive.

## SEC filing metadata
- accession: 0000805928-24-000135
- form_type: 8-K
- ticker: AXGN
- cik: 0000805928
- company_name: Axogen, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/805928/000080592824000135/0000805928-24-000135-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/805928/000080592824000135/axgn-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000805928-24-000135
- JSON: https://secwatch.observer/filing/0000805928-24-000135.json
- Plain text: https://secwatch.observer/filing/0000805928-24-000135.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.